argenx SE — FY2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019; filed March 31, 2020. This is an annual report, not a standalone 2019 fourth-quarter filing. Financial statements are prepared under IFRS as issued by the IASB and audited with an unqualified opinion.
Business context
argenx is a clinical-stage biotechnology company developing antibody therapies for autoimmune disease, hematology and cancer. It had no approved products and no product-sales revenue in 2019; reported revenue came from collaborations and related research and development services, milestones and upfront payments. Lead programs included efgartigimod and partnered cusatuzumab.
Financial results and liquidity
| Metric (€ millions, except per-share data) | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | 69.8 | 21.5 | +225% |
| Other operating income | 12.8 | 7.7 | +65% |
| Research and development expense | 197.7 | 83.6 | +136% |
| Selling, general and administrative expense | 64.6 | 27.5 | +135% |
| Operating loss | (178.6) | (81.8) | Loss widened 118% |
| Net loss | (163.0) | (66.6) | Loss widened 145% |
| Basic and diluted loss per share | (€4.22) | (€1.99) | |
| Cash, cash equivalents and current financial assets | 1,335.8 | 564.6 | +137% |
| Total assets | 1,433.3 | 578.5 | |
| Total liabilities | 382.6 | 40.1 | |
| Total equity | 1,050.7 | 538.4 |
Revenue comprised €22.4 million of upfront-payment recognition, €28.1 million of milestone revenue and €19.3 million of R&D service fees. Significant losses reflect a rapidly expanding development and commercial-readiness effort. No conventional profit margin is meaningful for this pre-commercial company.
Net cash from operating activities was €134.6 million, versus €53.8 million used in 2018. Investing activities used €744.3 million, principally reflecting €708.1 million invested in current financial assets and the Halozyme technology license. Financing activities provided €659.4 million, including €479.2 million net proceeds from the November global offering and €176.7 million from the Johnson & Johnson-affiliated equity investment. Cash and cash equivalents alone ended the year at €331.3 million; the larger €1.336 billion liquidity figure also includes current financial assets.
The filing reports no ongoing material financing commitments such as credit lines or guarantees. Lease liabilities were €6.5 million at year-end. Contractual obligations included €91.4 million of purchase obligations, mainly manufacturing-related; disclosed commitments included approximately €53.4 million for efgartigimod, €34.4 million for cusatuzumab and €3.6 million for ARGX-117. The company reported no off-balance-sheet arrangements.
Material changes versus 2018
- Revenue rose substantially following collaboration milestones and recognition of Janssen-related upfront and R&D amounts. Of the €300 million Janssen upfront cash payment, revenue is recognized over the service period; €289.0 million remained deferred at year-end across current and non-current liabilities.
- R&D expense more than doubled, with efgartigimod external R&D costs rising to €84.2 million and cusatuzumab costs to €38.7 million as trials and manufacturing advanced. R&D headcount increased from 75 to 118.
- SG&A increased to €64.6 million, including hiring and preparation for potential U.S. commercialization; SG&A headcount rose from 30 to 70.
- Liquidity increased after the November 2019 offering, the Janssen-related equity investment and collaboration receipts. Outstanding ordinary shares rose to 42,761,528 at year-end.
- argenx adopted IFRS 16 for leases in 2019, recognizing right-of-use assets and lease liabilities. The filing states this did not significantly affect financial-performance metrics.
Outlook, commentary and risks
- Management expected existing cash, cash equivalents and current financial assets to fund operating expenses and capital requirements for at least the next 12 months, based on then-current assumptions. It also expected continuing significant losses and rising development, manufacturing and commercialization costs.
- As of the filing, topline Phase 3 ADAPT results for efgartigimod in generalized myasthenia gravis were expected by mid-2020, with a potential BLA submission in Q4 2020 if results supported it. The company targeted a potential U.S. launch in 2021, subject to approval.
- Additional efgartigimod development was planned in ITP, pemphigus vulgaris and CIDP. The filing described a Phase 3 ITP program and anticipated further ITP and PV trials in 2020; these were plans, not assured outcomes. Cusatuzumab development with Janssen included AML and high-risk MDS trials.
- COVID-19 was identified as a potential source of trial-enrollment, site, supply-chain and operational disruption, with possible effects on timelines, costs and financing conditions. The impact was uncertain.
- Key risks include clinical-trial failure or delay, regulatory and manufacturing setbacks, dependence on collaborators and contract manufacturers, competition, reimbursement and pricing pressure, patent disputes, foreign-exchange exposure and potential need for additional capital. The company reported no current legal, governmental or arbitration proceedings and no cash dividends were expected in the foreseeable future.
- The company reported that a material weakness in internal control over financial reporting identified at December 31, 2018 had been remediated; management and the auditor concluded controls were effective at December 31, 2019. The financial-statement audit was unqualified; the auditor highlighted collaboration-revenue accounting and R&D accrual estimates as critical audit matters.
Important facts for investors to verify
- Whether the reported cash and current financial assets remain available as expected, including liquidity, investment composition and currency exposure.
- Clinical-trial results, regulatory progress and actual timing for efgartigimod and cusatuzumab, compared with the filing’s stated expectations.
- The assumptions, cost-to-complete estimates and revenue-recognition schedule underlying the €289.0 million Janssen-related deferred revenue balance.
- Whether collaboration cost-sharing, milestone and royalty terms—and substantial Lonza manufacturing commitments—change as programs advance.
- The evolving effects of COVID-19 on trial execution, manufacturing, expenses and the stated cash runway.
- Potential dilution from equity financing and share-based compensation; 4.36 million employee-plan options were outstanding at December 31, 2019.